Patient Surveillance After Cancer Treatment

Dr. Frank E. Johnson, MD

• 1. Overview.- 2. Introduction to Cancer Surveillance Strategies.- 3. Using Decision Analysis to Model Cancer Surveillance.- 4. Cancer Survivorship: Monitoring the Long-Term and Late Effects of Treatment.- 5. Upper Aerodigestive Tract Carcinoma.- 6. Upper Aerodigestive Tract Carcinoma Surveillance Counterpoint: Europe.- 7. Upper Aerodigestive Tract Carcinoma Surveillance Counterpoint: Japan.- 8. Upper Aerodigestive Tract Carcinoma Surveillance Counterpoint: Canada.- 9. Thyroid (Papillary, Follicular, Medullary, Hürthle Cell) Carcinoma.- 10. Thyroid (Papillary, Follicular, Medullary, Hürthle Cell) Carcinoma Surveillance Counterpoint: Australia.- 11. Thyroid (Papillary, Follicular, Medullary, Hürthle Cell) Carcinoma Surveillance Counterpoint: Japan.- 12. Lung Carcinoma.- 13. Lung Carcinoma Surveillance Counterpoint: Australia.- 14. Lung Carcinoma Surveillance Counterpoint: Japan.- 15. Lung Carcinoma Surveillance Counterpoint: Canada.- 16. Esophagus Carcinoma.- 17. Esophagus Carcinoma Surveillance Counterpoint: Australia.- 18. Esophagus Carcinoma Surveillance Counterpoint: Japan.- 19. Stomach.- 20. Stomach Carcinoma Surveillance Counterpoint: USA.- 21. Stomach Carcinoma Surveillance Counterpoint: Japan.- 22. Pancreatic Adenocarcinoma.- 23. Pancreatic Adenocarcinoma Surveillance Counterpoint: USA.- 24. Pancreatic Adenocarcinoma Surveillance Counterpoint: Europe.- 25. Pancreatic Adenocarcinoma Surveillance Counterpoint: Japan.- 26. Pancreatic Adenocarcinoma Surveillance Counterpoint: Canada.- 27. Liver and Biliary Tract Carcinoma.- 28. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Europe.- 29. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Australia.- 30. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Japan.- 31. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Canada.- 32. Colon and Rectum Carcinoma.- 33. Colon and Rectum Carcinoma Surveillance Counterpoint: USA.- 34. Colon and RectumCarcinoma Surveillance Counterpoint: Australia.- 35. Colon and Rectum Carcinoma Surveillance Counterpoint: Japan.- 36. Colon and Rectum Carcinoma Surveillance Counterpoint: Canada.- 37. Anal Carcinoma.- 38. Anal Carcinoma Surveillance Counterpoint: USA.- 39. Anal Carcinoma Surveillance Counterpoint: Australia.- 40. Anal Carcinoma Surveillance Counterpoint: Japan.- 41. Anal Carcinoma Surveillance Counterpoint: Canada.- 42. Soft Tissue Sarcoma.- 43. Soft Tissue Sarcoma Surveillance Counterpoint: USA.- 44. Soft-Tissue Sarcoma Surveillance Counterpoint: Japan.- 45. Soft Tissue Sarcoma Surveillance Counterpoint: Canada.- 46. Osteogenic Sarcoma and Dedifferentiated Chondrosarcoma.- 47. Osteogenic Sarcoma and Dedifferentiated Chondrosarcoma Surveillance Counterpoint: Japan.- 48. Osteogenic Sarcoma and Dedifferentiated Chondrosarcoma Surveillance Counterpoint: Canada.- 49. Cutaneous Melanoma.- 50. Cutaneous Melanoma Surveillance Counterpoint: USA.- 51. Cutaneous Melanoma Surveillance Counterpoint: Australia.- 52. Cutaneous Melanoma Surveillance Counterpoint: Japan.- 53. Breast Carcinoma.- 54. Breast Carcinoma Surveillance Counterpoint: USA.- 55. Breast Carcinoma Surveillance Counterpoint: Europe.- 56. Breast Carcinoma Surveillance Counterpoint: Australia.- 57. Breast Carcinoma Surveillance Counterpoint: Japan.- 58. Endometrial Carcinoma.- 59. Endometrial Cancer Surveillance Counterpoint: USA.- 60. Endometrial Cancer Surveillance Counterpoint: USA.- 61. Carcinoma of the Endometrium Surveillance Counterpoint: Japan.- 62. Endometrial Carcinoma Surveillance Counterpoint: Canada.- 63. Cervical Carcinoma.- 64. Cervical Carcinoma Surveillance Counterpoint: USA.- 65. Cervical Carcinoma Surveillance Counterpoint: Japan.- 66. Cervical Carcinoma Surveillance Counterpoint: Canada.- 67. Vaginal and Vulvar Carcinoma.- 68. Vaginal and Vulvar Carcinoma Surveillance Counterpoint: Japan.- 69. Ovarian Carcinoma.- 70. Ovarian Carcinoma Surveillance Counterpoint:USA.- 71. Ovarian Cancer Surveillance Counterpoint: Europe.- 72. Ovarian Cancer Surveillance Counterpoint: Japan.- 73. Renal Carcinoma.- 74. Renal Carcinoma Surveillance Counterpoint: Europe.- 75. Renal Carcinoma Surveillance Counterpoint: Japan.- 76. Renal Carcinoma Surveillance Counterpoint: Canada.- 77. Urinary Bladder Carcinoma.- 78. Urinary Bladder Carcinoma Surveillance Counterpoint: Japan.- 79. Urinary Bladder Carcinoma Surveillance Counterpoint: Canada.- 80. Prostate Carcinoma.- 81. Prostate Carcinoma Surveillance Counterpoint: USA.- 82. Prostate Carcinoma Surveillance Counterpoint: USA.- 83. Prostate Carcinoma Surveillance Counterpoint: Europe.- 84. Prostate Carcinoma Surveillance Counterpoint: Japan.- 85. Prostate Carcinoma Surveillance Counterpoint: Canada.- 86. Testicle Carcinoma.- 87. Testicle Carcinoma Surveillance Counterpoint: USA.- 88. Testicle Carcinoma Surveillance Counterpoint: Australia.- 89. Testicle Carcinoma Surveillance Counterpoint: Japan.- 90. Lymphoma.- 91. Lymphoma Surveillance Counterpoint: USA.- 92. Lymphoma Surveillance Counterpoint: Japan.- 93. Lymphoma (Following Autologous Stem Cell Transplant).- 94. Lymphoma (Following Autologous Stem Cell Transplant) Surveillance Counterpoint: Japan.- 95. Leukemia.- 96. Leukemia Surveillance Counterpoint: USA.- 97. Leukemia Surveillance Counterpoint: Japan.- 98. Multiple Myeloma.- 99. Multiple Myeloma Surveillance Counterpoint: USA.- 100. Multiple Myeloma Surveillance Counterpoint: Australia.- 101. Multiple Myeloma Surveillance Counterpoint: Japan.- 102. Multiple Myeloma Surveillance Counterpoint: Canada.- 103. Glioma of the Central Nervous System.- 104. Glioma of the Central Nervous System Surveillance Counterpoint: Europe.- 105. Glioma of the Central Nervous System Surveillance Counterpoint: Australia.- 106. Glioma of the Central Nervous System Surveillance Counterpoint:Japan.

From the reviews: "This book discusses surveillance strategies for patients completing curative-intent primary treatment for cancer. ... Members of the oncology treatment team as well as primary care health professionals who provide post-treatment follow-up survivorship care will benefit from this informative, disease-specific resource. ... This is an extremely valuable and useful compilation of cancer site-specific surveillance guidelines for follow-up of asymptomatic patients who have completed primary treatment with curative intent." (Judith G. Abramson, Doody's Book Reviews, September, 2013) "Patient Surveillance After Cancer Treatment is a well-written, well-organized reference designed to speak to any practicing oncologist or primary care provider that follows cancer patients after treatment for curative intent. ... This is a great text and reference to any clinically practicing oncologist, primary care provider, survivorship program, and training physician of any level. Patient Surveillance After Cancer Treatment will continue to prove itself useful and will be readily available in our library." (Nima Nabavizadeh and David Elliott, Journal of Radiation Oncology, Vol. 2 (3), September, 2013)